CELG
$109.98
Celgene
($.04)
(.04%)
CELG
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $2.88
Revenue:  $4.60 Bil
Thursday
Jan 30
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CELG reports earnings?
Beat
Meet
Miss

Where is CELG's stock price going from here?
Up
Flat
Down
Stock chart of CELG
Analysts
Summary of analysts' recommendations for CELG
Score
Grade
Pivots
Resistance
$111.54
$111.03
$110.53

$110.02

Support
$109.52
$109.01
$108.51
Tweet
Growth
Description
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsInterCeptJohnson & JohnsonMylanZoetisEndo International plcUltragenyx PharmaceuticalBristol-Myers Squibb